Ingrid G. Rekeland

Haukeland University Hospital — Norway

Medicine · Health Sciences

9h-index610citations15works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fibromyalgia and Chronic Fatigue Syndrome Research(12), Genetic Neurodegenerative Diseases(3), Advanced Proteomics Techniques and Applications(2), Long-Term Effects of COVID-19(2), Peripheral Neuropathies and Disorders(2)

Publications15 total

Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study
Frontiers in Medicine·2025· 1 citedOpen Access
Charting the Circulating Proteome in ME/CFS: Cross System Profiling and Mechanistic insights
2025Open Access
Charting the Circulating Proteome in ME/CFS: Cross System Profiling and Mechanistic Insights
SSRN Electronic Journal·2025Open Access
Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
PLoS ONE·2024· 6 citedOpen Access
Endothelial dysfunction in ME/CFS patients
PLoS ONE·2023· 41 citedOpen Access
Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients
PLoS ONE·2022· 12 citedOpen Access
A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome
JCI Insight·2021· 61 citedOpen Access
Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci
Brain Behavior and Immunity·2021· 10 citedOpen Access
Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome–Results From Open-Label Cyclophosphamide Intervention Study
Frontiers in Medicine·2021· 30 citedOpen Access
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study
Frontiers in Medicine·2020· 31 citedOpen Access
Table of Contents
Clinical Therapeutics·2019Open Access
B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Annals of Internal Medicine·2019· 88 cited
Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome
Clinical Therapeutics·2018· 5 citedOpen Access
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome
JCI Insight·2016· 201 citedOpen Access
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment
PLoS ONE·2015· 124 citedOpen Access

Frequent Co-authors

Øystein Fluge(15), Olav Mella(15), Kari Sørland(14), Kristin Risa(12), Kine Alme(12), Karl Johan Tronstad(8), Olav Dahl(7), Ove Bruland(5), Alexander Fosså(4), Sissel E. Dyrstad(3), Irini Ktoridou-Valen(3), Katarina Lien(3), Ingrid Herder(3), Hanne Thürmer(3), Christoph Schäfer(3), Fredrik Hoel(3), August Hoel(3), Hans‐Peter Marti(3), Dipak Sapkota(2), Sigrid Lunde(2)